Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+breast cancer cells

被引:9
|
作者
Murad, Rabi [1 ]
Avanes, Arabo [2 ]
Ma, Xinyi [1 ]
Geng, Shuhui [2 ]
Mortazavi, Ali [1 ]
Momand, Jamil [2 ]
机构
[1] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92617 USA
[2] Calif State Univ Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90032 USA
基金
美国国家卫生研究院;
关键词
breast cancer; Herceptin; trastuzumab; drug resistance; FoxJ3; Sox2; ATAC-seq; differentially expressed genes; METASTATIC BREAST-CANCER; T-DARPP; EXPRESSION; RECEPTOR; CHEMOTHERAPY; WOMEN; LINES; SEQ;
D O I
10.1016/j.gene.2021.145808
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We set out to uncover transcriptome and chromatin landscape changes that occur in HER2 + breast cancer (BC) cells upon acquiring resistance to trastuzumab. RNA-seq analysis was applied to two independently-derived BC cell lines with acquired resistance to trastuzumab (SKBr3.HerR and BT-474HerR) and their parental drugsensitive cell lines (SKBr3 and BT-474). Chromatin landscape analysis indicated that the most significant increase in accessibility in resistant cells occurs in PPP1R1B within a segment spanning introns 1b through intron 3. Footprint analysis of this segment revealed that FoxJ3 (within intron 2) and Pou5A1/Sox2 (within inton 3) transcription factor motifs are protected in resistant cells. Overall, 344 shared genes were upregulated in both resistant cell lines relative to their parental counterparts and 453 shared genes were downregulated in both resistant cell lines relative to their parental counterparts. In resistant cells, genes associated with autophagy and mitochondria organization are upregulated and genes associated with ribosome assembly and cell cycle are downregulated relative to parental cells. The five top upregulated genes in drug-resistant breast cancer cells are APOD, AZGP1, ETV5, ALPP, and PPP1R1B. This is the first report of increased chromatin accessibility within PPP1R1B associated with its t-Darpp transcript increase, and points to a possible mechanism for its activation in trastuzumab-resistant cells.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Trastuzumab sensitizes HER2+breast cancer to increase efficacy of chemotherapy in vitro and in vivo
    Shah, Alay
    Jarrett, Angela
    Syed, Anum
    Yankeelov, Thomas
    Sorace, Anna
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+breast cancer
    Dackus, Gwen M. H. E.
    Jozwiak, Katarzyna
    van der Wall, Elsken
    van Diest, Paul J.
    Hauptmann, Michael
    Siesling, Sabine
    Sonke, Gabe S.
    Linn, Sabine C.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 817 - 830
  • [43] Genomics of HER2+breast cancer
    Perou, C.
    CANCER RESEARCH, 2022, 82 (04)
  • [44] On the role of calpain in regulation of HER2 and resistance to trastuzumab in breast cancer cells
    Kulkarni, S.
    Reddy, K. B.
    Esteva, F. J.
    Budd, T. G.
    Moore, H. C. F.
    Tubbs, R. R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S205 - S206
  • [45] Effect of cyclin E overexpression on resistance to trastuzumab and phosphorylation of SMAD3 in HER2+breast cancer.
    Kandagatla, Pridvi
    Decker, Joseph
    Wan, Lei
    Bernstein, Regan
    Shea, Lonnie
    Jeruss, Jacqueline Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+breast cancer
    Magali Mondaca, Joselina
    Castro Guijarro, Ana Carla
    Ines Flamini, Marina
    Matias Sanchez, Angel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 363 - 377
  • [47] Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+breast cancer
    Lammers, Philip E.
    Dank, Magdolna
    Masetti, Riccardo
    Abbas, Richat
    Hilton, Fiona
    Coppola, Jennifer
    Jacobs, Ira
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 266 - 273
  • [48] Soluble TNFa induced mucin 4 is a mediator of trastuzumab resistance and of an immunosuppressive tumor microenvironment in HER2+breast cancer
    Bruni, Sofia
    De Martino, Mara
    Mauro, Florencia
    Maria de la Parra, Lucia Santa
    Elizalde, Patricia
    Schillaci, Roxana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [49] Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+breast cancer cells
    Karakas, Bahriye
    Ozmay, Yeliz
    Basaga, Huveyda
    Gul, Ozgur
    Kutuk, Ozgur
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2018, 1865 (08): : 1073 - 1087
  • [50] Soluble TNFα overcomes lapatinib resistance in HER2+breast cancer
    Bruni, Sofia
    Mauro, Florencia L.
    De Martino, Mara
    Deamicis, Agustina Roldan
    Mercogliano, Maria F.
    Schillaci, Roxana
    Elizalde, Patricia, V
    CANCER RESEARCH, 2020, 80 (16)